Benjamin M. Greenberg, MD, MHS is a Professor in the Department of Neurology at the University of Texas Southwestern Medical Center in Dallas, Texas. He serves as Vice Chair of Translational and Clinical Research in the Department of Neurology and Director of the Perot Foundation Neurosciences Translational Research Center within the O’Donnell Brain Institute.
Dr. Greenberg received his Bachelor’s Degree from The Johns Hopkins University and his Masters Degree in Molecular Microbiology and Immunology from The Johns Hopkins School of Public Health in Baltimore, Maryland. He attended medical school at Baylor College of Medicine in Houston, Texas and was elected to the Alpha Omega Alpha honor society. He completed an internship in medicine at Rush Presbyterian-St. Luke’s Medical Center in Chicago, Illinois before going on to his residency in neurology at The Johns Hopkins Hospital in Baltimore, MD. After completing residency he joined the faculty at Johns Hopkins and completed a post-doctoral fellowship in neurovirology. He was a member of the Richard T. Johnson Division of Neuroimmunology and Neurological Infections. He was co-Director of the Transverse Myelitis Center and Director of the Encephalitis Center.
In January of 2009, he was recruited to the University of Texas Southwestern Medical Center to Direct a new program in transverse myelitis and neuromyelitis optica. He founded the pediatric demyelinating disease program at Children’s Medical Center.
His research interests are in both the diagnosis and treatment of transverse myelitis, neuromyelitis optica, multiple sclerosis and encephalitis. He is actively involved in developing better ways to diagnose and prognosticate for patients with these disorders. He has led an effort to improve biorepository development and has created uniform protocols for sample handling and analysis. As part of this initiative his research has identified novel biomarkers that may be able to distinguish between patients with various neurologic disorders. He also coordinates trials that study new treatments to prevent neurologic damage and restore function to those who have already been affected.